Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1580-1588

  Ustun, Celalettin ^a   Slabý, Jiří ^a   Shanley, Ryan M ^b   Vydra, Jan ^a   Smith, Angela R ^c   Wagner, John E ^c   Weisdorf, Daniel J ^a   Young, Jo Anne H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

HCT (hematopoietic cell transplantation); Human parainfluenza virus; Infection; Reduced intensity conditioning; Respiratory virus

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN;

ARTICLE; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARAINFLUENZA VIRUS INFECTION; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; RESPIROVIRUS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; UNITED STATES; UNRELATED DONORS;

EID: 84866163372     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.04.012     Document Type: Article

References (34)

1. Wendt C.H., Weisdorf D.J., Jordan M.C., Balfour H.H., Hertz M.I. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992, 326:921-926.
2. Reed G., Jewett P.H., Thompson J., Tollefson S., Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis 1997, 175:807-813.
3. Arisoy E.S., Demmler G.J., Thakar S., Doerr C. Meningitis due to parainfluenza virus type 3: report of two cases and review. Clin Infect Dis 1993, 17:995-997.
4. Henderson F.W. Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses. Semin Respir Infect 1987, 2:112-121.
5. Henderson F.W., Collier A.M., Sanyal M.A., et al. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 1982, 306:1377-1383.
6. Cox D.R. Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972, 34:187-220.
7. Apalsch A.M., Green M., Ledesma-Medina J., Nour B., Wald E.R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 1995, 20:394-399.
8. Peck A.J., Englund J.A., Kuypers J., et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007, 110:1681-1688.
9. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001, 98:573-578.
10. Karp D., Willis J., Wilfert C.M. Parainfluenza virus II and the immunocompromised host. Am J Dis Child 1974, 127:592-593.
11. Cortez K.J., Erdman D.D., Peret T.C., et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001, 184:1093-1097.
12. Martino R., Porras R.P., Rabella N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005, 11:781-796.
13. Lewis V.A., Champlin R., Englund J., et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996, 23:1033-1037.
14. Raboni S.M., Nogueira M.B., Tsuchiya L.R., et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003, 76:142-146.
15. Machado C.M., Boas L.S., Mendes A.V., et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003, 31:695-700.
16. Chakrabarti S., Collingham K.E., Holder K., Oyaide S., Pillay D., Milligan D.W. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis 2000, 31:1516-1518.
17. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
18. Warlick E.D., Tomblyn M., Cao Q., et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011, 17:1025-1032.
19. Bachanova V., Brunstein C.G., Burns L.J., et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009, 43:237-244.
20. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009, 15:367-369.
21. Chakrabarti S., Avivi I., Mackinnon S., et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002, 119:1125-1132.
22. Knott A.M., Long C.E., Hall C.B. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr Infect Dis J 1994, 13:269-273.
23. Bellau-Pujol S., Vabret A., Legrand L., et al. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods 2005, 126:53-63.
24. Aguilar J.C., Pérez-Breña M.P., García M.L., Cruz N., Erdman D.D., Echevarría J.E. Detection and identification of human parainfluenza viruses 1, 2, 3, and 4 in clinical samples of pediatric patients by multiplex reverse transcription-PCR. J Clin Microbiol 2000, 38:1191-1195.
25. Kuypers J., Wright N., Ferrenberg J., et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol 2006, 44:2382-2388.
26. Templeton K.E., Scheltinga S.A., Beersma M.F., Kroes A.C., Claas E.C. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza A and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J Clin Microbiol 2004, 42:1564-1569.
27. van Kraaij M.G., van Elden L.J., van Loon A.M., et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis 2005, 40:662-669.
28. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
29. Safdar A., Rodriguez G.H., Mihu C.N., et al. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010, 45:339-347.
30. Sparrelid E., Ljungman P., Ekelöf-Andström E., et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997, 19:905-908.
31. Crooks B.N., Taylor C.E., Turner A.J., et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000, 26:1097-1102.
32. Lewinsohn D.M., Bowden R.A., Mattson D., Crawford S.W. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996, 40:2555-2557.
33. Karron R.A., Wright P.F., Hall S.L., et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107-1114.
34. Karron R.A., Wright P.F., Newman F.K., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172:1445-1450.